INTERACTION OF INTRAVENOUS DILTIAZEM WITH LOVASTATIN

静脉注射地尔硫卓与洛伐他汀的相互作用

• 批准号: 6291160
• 负责人: D CRAIG BRATER
• 金额: $ 0.04万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6291160
• 关键词: clinical research; clinical trials; cytochrome P450; diltiazem; drug interactions; gastrointestinal system; human subject; intravenous administration; liver; lovastatin; oral administration; pharmacokinetics

This study will assess whether or not a commonly used calcium antagonist, namely diltiazem, that is known to have the capacity to block cytochrome P450 3A4, and which has been shown in our previous study to result in a drug interaction with lovastatin when given orally will produce the same interaction when given by the parenteral route. The protocol will evaluate whether lovastatin is susceptible to pharmacokinetic interactions that effect the formation of active moieties when diltiazem is given intravenously. The specific aim of the study is to determine whether the observed interaction of diltiazem with lovastatin, occurs at the intestinal level or in the liver. Intravenous therapy with diltiazem will help answer this question by bypassing the intestinal cytochrome P450 3A4.

本研究将评估一种常用的钙拮抗剂，即地尔硫卓，已知其具有阻断细胞色素P450 3A4的能力，并且在我们先前的研究中已显示其在口服给药时与洛伐他汀发生药物相互作用，当通过胃肠外途径给药时是否会产生相同的相互作用。 该方案将评价洛伐他汀是否易受影响地尔硫卓静脉给药时活性部分形成的药代动力学相互作用的影响。本研究的具体目的是确定观察到的地尔硫卓与洛伐他汀的相互作用是否发生在肠道水平或肝脏中。 静脉注射地尔硫卓治疗将有助于回答这个问题，绕过肠道细胞色素P450 3A4。